Stockholm-based biotech company BioLamina has secured a €20 million financing commitment from the European Investment Bank (EIB) to scale its technologies supporting next-generation cell therapies.
The funding is structured as venture debt, providing long-term capital while minimising dilution for existing shareholders.
Advancing Cell Therapy Development
Founded in 2009 by Karl Tryggvason and Kristian Tryggvason, BioLamina focuses on matrix biology and cell culture solutions that enable reliable growth and differentiation of stem cells and primary cells.
Its core innovation lies in laminin-based substrates—specialised proteins that provide a consistent environment for cell development, improving the quality and reproducibility of research and therapeutic applications.
Advertisement
Scaling Production And Technology
The €20 million financing will support expansion across manufacturing, product development, and overall business growth. BioLamina aims to scale its production capabilities to meet increasing demand from the rapidly evolving cell therapy sector.
Its technologies are already used in the development of treatments for conditions such as diabetes, Parkinson’s disease, heart failure, liver disease, and cancer.
Supporting Next-Generation Therapies
The firm’s Biolaminin® products are fully defined, animal-origin-free recombinant proteins used in clinical-stage cell therapy development. These solutions also contribute to more accurate, animal-free drug testing models.
As cell therapies move closer to widespread clinical use, the ability to produce high-quality, scalable cell products remains a key challenge—one BioLamina aims to address with its platform.
Backed By European Innovation Initiatives
The investment aligns with broader European programmes such as InvestEU, TechEU, and BioTechEU, which aim to strengthen innovation and competitiveness in the biotechnology sector.
Karl Nehammer highlighted the importance of scaling European innovation:
“Supporting companies like BioLamina ensures that scientific breakthroughs can grow into global businesses, strengthening competitiveness and improving public health.”
According to Klaus Langhoff-Roos, the timing is critical:
“Cell therapies are moving from promise to reality, but scaling production remains a major challenge. This financing allows us to expand our capabilities and support the next generation of therapies.”
About BioLamina
BioLamina is a Swedish biotech company specialising in laminin-based cell culture solutions. Its technologies enable reliable and scalable cell growth, supporting advances in regenerative medicine, drug discovery, and clinical-stage cell therapies.
